|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for LY96 |
 Gene summary |
| Basic gene Info. | Gene symbol | LY96 |
| Gene name | lymphocyte antigen 96 | |
| Synonyms | ESOP-1|MD-2|MD2|ly-96 | |
| Cytomap | UCSC genome browser: 8q21.11 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001195797.1, NM_015364.4, | |
| Description | myeloid differentiation protein-2protein MD-2 | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 605243 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000154589 | ||
| HPRD : 05579 | ||
| Vega : OTTHUMG00000164504 | ||
| Protein | UniProt: Q9Y6Y9 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_LY96 | |
| BioGPS: 23643 | ||
| Pathway | NCI Pathway Interaction Database: LY96 | |
| KEGG: LY96 | ||
| REACTOME: LY96 | ||
| Pathway Commons: LY96 | ||
| Context | iHOP: LY96 | |
| ligand binding site mutation search in PubMed: LY96 | ||
| UCL Cancer Institute: LY96 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0031663 | lipopolysaccharide-mediated signaling pathway | 19252480 | GO:0032496 | response to lipopolysaccharide | 12594207 | GO:0032497 | detection of lipopolysaccharide | 19252480 |
| Top |
| Ligand binding site mutations for LY96 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R90 | R90C | COAD | 1 | F126,I124 | K125Q | COAD | 1 | R90 | K91E | GBM | 1 | Y102 | D101H | HNSC | 1 | G123 | G123A | OV | 1 | L61 | G59E | SKCM | 1 | Y102 | D101N | SKCM | 1 | N26 | S27A | UCEC | 1 | F126,I124 | K125Q | UCEC | 1 | R90 | R90C | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for LY96 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | Y102 | D101N | -1.4243209 | Y102 | D101H | -1.3610012 | R90 | R90C | -1.3032631 | G123 | G123A | -0.93601627 | N26 | S27A | -0.58672322 | I124 | K125Q | -0.53124744 | F126 | K125Q | -0.53124744 | R90 | K91E | -0.51951072 | L61 | G59E | -0.061068553 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for LY96 from PDB |
| Top |
| Differential gene expression and gene-gene network for LY96 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for LY96 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0007097 | Carcinoma | 1 | Biomarker |
| umls:C0009404 | Colorectal Neoplasms | 1 | Biomarker |
| umls:C0027627 | Neoplasm Metastasis | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for LY96 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB02767 | 3-Hydroxy-Myristic Acid | Small molecule |  |
| Experimental | DB08231 | MYRISTIC ACID | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of LY96 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | LP5 | (R)-((2R,3S,4R,5R,6R)-3-HYDROXY-2-(HYDROXYMETHYL)-5-((R)-3-HYDROXYTETRADECANAMIDO)-6-(PHOSPHONOOXY)TETRAHYDRO-2H-PYRAN-4-YL) 3-HYDROXYTETRADECANOATE | 2e59 | A | L61 | LP4 | (R)-((2R,3S,4R,5S)-2-(HYDROXYMETHYL)-5-((R)-3-HYDROXYTETRADECANAMIDO)-3-(PHOSPHONOOXY)TETRAHYDRO-2H-PYRAN-4-YL) 3-HYDROXYTETRADECANOATE | 4g8a | D | L61 Y102 | NAG | ALDEHYDO-N-ACETYL-D-GLUCOSAMINE | 2e56 | A | N26 | NAG | ALDEHYDO-N-ACETYL-D-GLUCOSAMINE | 2e59 | A | N26 | LP4 | (R)-((2R,3S,4R,5S)-2-(HYDROXYMETHYL)-5-((R)-3-HYDROXYTETRADECANAMIDO)-3-(PHOSPHONOOXY)TETRAHYDRO-2H-PYRAN-4-YL) 3-HYDROXYTETRADECANOATE | 2e59 | A | R90 I124 | LP5 | (R)-((2R,3S,4R,5R,6R)-3-HYDROXY-2-(HYDROXYMETHYL)-5-((R)-3-HYDROXYTETRADECANAMIDO)-6-(PHOSPHONOOXY)TETRAHYDRO-2H-PYRAN-4-YL) 3-HYDROXYTETRADECANOATE | 4g8a | C | R90 I124 F126 | LP5 | (R)-((2R,3S,4R,5R,6R)-3-HYDROXY-2-(HYDROXYMETHYL)-5-((R)-3-HYDROXYTETRADECANAMIDO)-6-(PHOSPHONOOXY)TETRAHYDRO-2H-PYRAN-4-YL) 3-HYDROXYTETRADECANOATE | 4g8a | D | R90 I124 F126 | LP4 | (R)-((2R,3S,4R,5S)-2-(HYDROXYMETHYL)-5-((R)-3-HYDROXYTETRADECANAMIDO)-3-(PHOSPHONOOXY)TETRAHYDRO-2H-PYRAN-4-YL) 3-HYDROXYTETRADECANOATE | 4g8a | C | Y102 | E55 | ERITORAN TETRASODIUM | 2z65 | C | Y102 G123 | E55 | ERITORAN TETRASODIUM | 2z65 | D | Y102 G123 I124 |
| Top |
| Conservation information for LBS of LY96 |
| Multiple alignments for Q9Y6Y9 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |